论文部分内容阅读
对7例白血病脑膜转移患者脑室内注射阿糖胞苷(Ara-C)后,于24h 内分次收集的脑脊液及血浆样品,用反相HPLC 测定Ara-C 浓变(测脑脊液灵敏度为0.5μM,测血浆灵敏度为1μM),并可分离得原药Ara-C 及代谢物阿糖尿苷(Ara-U)。结果表明,经髓鞘向脑室注入Ara-C 30mg 后,脑脊液中初始浓度可达2mM以上,并保持在1μM 以上达24h(据组织培养试验,浓度在0.4μM 即具抗肿瘤作用)。外周血Ara-C 浓度低于1μM 未能测出。如静脉注射给药,Ara-C 剂量即
Cerebrospinal fluid (CSF) and plasma samples collected in 24 hours after intracerebroventricular injection of cytarabine (Ara-C) in 7 leukemic patients with leukemia were assayed for Ara-C concentration by reverse phase HPLC (CSF sensitivity was 0.5 μM , Measuring the plasma sensitivity of 1μM), and can be separated from the original drug Ara-C and the metabolite arabinoside (Ara-U). The results showed that the initial concentration of cerebrospinal fluid after the myelin into the ventricle of Ara-C 30mg up to 2mM above, and maintained at 1μM for up to 24h (according to tissue culture experiments, the concentration of 0.4μM that is anti-tumor effect). Peripheral blood Ara-C concentrations below 1 μM failed to measure. Such as intravenous injection, Ara-C dose that